Discovery Value Fund Has $881,000 Position in Intellia Therapeutics, Inc. $NTLA

Discovery Value Fund trimmed its position in Intellia Therapeutics, Inc. (NASDAQ:NTLA) by 57.2% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 97,976 shares of the company’s stock after selling 130,725 shares during the period. Intellia Therapeutics accounts for 2.3% of Discovery Value Fund’s investment portfolio, making the stock its 2nd biggest position. Discovery Value Fund owned about 0.08% of Intellia Therapeutics worth $881,000 at the end of the most recent quarter.

Several other large investors have also recently bought and sold shares of NTLA. Contrarius Group Holdings Ltd boosted its holdings in Intellia Therapeutics by 279.4% in the 3rd quarter. Contrarius Group Holdings Ltd now owns 5,889,936 shares of the company’s stock valued at $101,719,000 after purchasing an additional 4,337,428 shares during the period. ARK Investment Management LLC boosted its holdings in Intellia Therapeutics by 19.2% in the 4th quarter. ARK Investment Management LLC now owns 14,207,324 shares of the company’s stock valued at $127,724,000 after purchasing an additional 2,288,146 shares during the period. Vanguard Group Inc. boosted its holdings in Intellia Therapeutics by 17.8% in the 4th quarter. Vanguard Group Inc. now owns 13,010,001 shares of the company’s stock valued at $116,960,000 after purchasing an additional 1,965,181 shares during the period. Jupiter Asset Management Ltd. bought a new position in Intellia Therapeutics in the 3rd quarter valued at $23,519,000. Finally, Farallon Capital Management LLC bought a new stake in shares of Intellia Therapeutics during the 3rd quarter worth $10,486,000. 88.77% of the stock is owned by institutional investors.

Analysts Set New Price Targets

A number of analysts have recently issued reports on NTLA shares. JonesTrading raised shares of Intellia Therapeutics from a “hold” rating to a “buy” rating and set a $29.00 price objective for the company in a report on Wednesday, March 4th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Intellia Therapeutics in a report on Tuesday, April 21st. Morgan Stanley lifted their price objective on shares of Intellia Therapeutics from $11.00 to $15.00 and gave the stock an “equal weight” rating in a report on Monday, April 27th. Wedbush reaffirmed a “neutral” rating and set a $12.00 price objective on shares of Intellia Therapeutics in a report on Tuesday, May 12th. Finally, The Goldman Sachs Group lifted their price objective on shares of Intellia Therapeutics from $8.00 to $9.00 and gave the stock a “sell” rating in a report on Tuesday, April 28th. One investment analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating, ten have given a Hold rating and three have given a Sell rating to the company’s stock. According to data from MarketBeat, Intellia Therapeutics currently has a consensus rating of “Hold” and a consensus target price of $20.25.

Intellia Therapeutics Trading Up 1.2%

NTLA opened at $12.35 on Friday. The company has a market cap of $1.73 billion, a P/E ratio of -3.49 and a beta of 1.92. The business’s 50-day moving average price is $13.62 and its 200-day moving average price is $12.30. Intellia Therapeutics, Inc. has a 12 month low of $7.95 and a 12 month high of $28.25.

Intellia Therapeutics (NASDAQ:NTLA) last released its quarterly earnings data on Monday, May 11th. The company reported ($0.81) EPS for the quarter, topping the consensus estimate of ($0.92) by $0.11. The firm had revenue of $15.05 million for the quarter, compared to the consensus estimate of $13.81 million. Intellia Therapeutics had a negative return on equity of 57.47% and a negative net margin of 597.04%.During the same quarter in the previous year, the business earned ($1.10) earnings per share. Equities research analysts forecast that Intellia Therapeutics, Inc. will post -3.18 earnings per share for the current fiscal year.

About Intellia Therapeutics

Intellia Therapeutics, Inc (NASDAQ: NTLA) is a clinical‐stage biotechnology company focused on developing potentially curative genome editing therapies using the CRISPR/Cas9 platform. The company’s research spans both in vivo and ex vivo applications of CRISPR/Cas9, aiming to correct or disable disease‐causing genes with a single administration. Intellia’s lead in vivo program targets transthyretin amyloidosis (ATTR) by delivering CRISPR/Cas9 machinery directly to the liver, while additional preclinical efforts pursue treatments for hemophilia A, hereditary angioedema and other genetic disorders.

Beyond its in vivo pipeline, Intellia collaborates with strategic partners to extend the impact of its genome editing approach.